A review of the effects of levamisole on erythrocyte sedimentation rate, acute phase proteins, and anemia.
A statistically significant decrease of erythrocyte sedimentation rate (ESR) is seen in levamisole-treated rheumatoid arthritis (RA) patients. While there is a correlation between ESR decrease and clinical improvement, in a few patients ESR remains unchanged in spite of a good clinical result. A decrease of acute phase proteins and an increase in hemoglobin and hematocrit have also been reported with levamisole.
D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D001798:Blood Proteins / Q000032:analysis*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006046:Gold / Q000627:therapeutic use; D006242:Haptoglobins / Q000032:analysis; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D010396:Penicillamine / Q000627:therapeutic use; D010919:Placebos; D000515:alpha 1-Antitrypsin / Q000032:analysis
D001798:Blood Proteins; D006242:Haptoglobins; D006454:Hemoglobins; D010919:Placebos; D000515:alpha 1-Antitrypsin; D007978:Levamisole; D006046:Gold; D002097:C-Reactive Protein; D010396:Penicillamine